Mitsubishi Tanabe notifies Kolon Life Science cancellation of ‘Invossa’ technology agreement
Kolon Life Science(CEO Woo-Seok Lee) announced on the 19th Mitsubishi Tanabe Pharma(MTPC) notified the company cancellation of Invossa technology export and to return the upfront payment of JPY 2.5 billion(approx. KRW 25 billion).
MTPC notified the cancellation because Kolon Life Science did not...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.